You are here

Article Text

Article menu

Download PDFPDF

Lung cancer: from virtual contact to invasive procedures
P256 Targeted stem cells expressing trail as a therapy for lung cancer tactical: a phase i/ii trial
Free
  1. AV Davies1,*,
  2. EK Sage1,*,
  3. K Kolluri1,
  4. B Weil2,
  5. R Vitorino Tendeiro Pereira Rego2,
  6. A Edwards1,
  7. O Bain2,
  8. G Santilli3,
  9. D Fullen4,
  10. K Champion5,
  11. A Day5,
  12. G Wheeler5,
  13. B Popova5,
  14. A Thrasher3,
  15. M Forster6,
  16. MW Lowdell2,
  17. SM Janes1
  1. 1Lungs for Living Research Centre, UCL, London, UK
  2. 2Centre for Cell, Gene and Tissue Therapeutics, Royal Free Hospital, London, UK
  3. 3UCL Great Ormond Street Institute of Child Health, London, UK
  4. 4Translational Research Office, UCL, London, UK
  5. 5Cancer Research UK and UCL Cancer Trials Centre, London, UK
  6. 6University College London Hospital, London, UK
  7. *Joint first author

Abstract

Introduction Lung cancer is the leading cause of cancer death worldwide with over 70% presenting with incurable disease and few effective treatments. We previously demonstrated that mesenchymal stem cells (MSCs) transduced to express TNF-related apoptosis inducing ligand (TRAIL), will home to and induce apoptosis of tumour cells in vitro and reduce tumour growth in multiple in vivo models. We are now undertaking a clinical trial to assess the therapeutic efficacy of this genetically modified cell therapy.

Aim To evaluate the safety and anti-tumour activity of MSCTRAIL in combination with chemotherapy in patients with metastatic lung adenocarcinoma.

Manufacturing Methods MSCs were isolated from unrelated umbilical cord donors and characterised as MSCs according to international criteria. Cells from individual donors were thawed and transduced with a lentiviral vector encoding for TRAIL. Successful transduction was confirmed by flow cytometry and cells were subsequently pooled and seeded into a multilayer bioreactor. Once confluent, cells were harvested to form the primary seed stock (PSS). PSS vials underwent further expansion rounds to form a working cell stock (WCC) and subsequent investigational medicinal product (IMP) ready for patient dosing.

Trial Design Patients with stage IIIB/IV adenocarcinoma of the lung (EGFR and EML4-ALK negative) will be eligible for enrolment Phase I is a dose de-escalation study (figure 1A) where patients will receive pemetrexed and cisplatin on day 1 then 4 × 108 MSC-TRAIL cells on day 2 of a 21 day cycle for 3 cycles. Dose limiting toxicities will be recorded. Phase II is a single blinded, randomised, placebo controlled trial consisting of standard chemotherapy and either MSC-TRAIL or placebo (figure 1B). Safety data will be collected and efficacy will be assessed using CT with RECIST (v1.1) criteria at 12 weeks. All patients will be monitored for up to 2 years.

Abstract P256 Figure 1A
Abstract P256 Figure 1A

Phase I Schema.

Abstract P256 Figure 1B
Abstract P256 Figure 1B

Phase II Schema.

Outcomes Phase I primary outcome is safety and tolerability of MSC-TRAIL.

Phase II is tumour response rate by RECIST (v 1.1) criteria at 12 weeks.

Conclusion We have produced a viable working bank of genetically modified stem cells, If therapy is effective we will plan to expand into larger phase III trials.

https://doi.org/10.1136/thoraxjnl-2017-210983.398

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.